ICER finds semaglutide more effective, but more expensiveThe Institute for Clinical and Economic Review (ICER) in the US has published its revised Evidence Report assessing the comparative...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events2 days ago